Literature DB >> 26495928

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements.

Maria Bjerke, Ulf Andreasson, Julia Kuhlmann, Erik Portelius, Josef Pannee, Piotr Lewczuk, Robert M Umek, Eugeen Vanmechelen, Hugo Vanderstichele, Erik Stoops, Jennifer Lewis, Manu Vandijck, Vesna Kostanjevecki, Andreas Jeromin, Salvatore J Salamone, Oliver Schmidt, Anja Matzen, Kairat Madin, Udo Eichenlaub, Tobias Bittner, Leslie M Shaw, Ingrid Zegers, Henrik Zetterberg, Kaj Blennow.   

Abstract

BACKGROUND: The cerebrospinal fluid (CSF) amyloid-β (Aβ42) peptide is an important biomarker for Alzheimer's disease (AD). Variability in measured Aβ42 concentrations at different laboratories may be overcome by standardization and establishing traceability to a reference system. Candidate certified reference materials (CRMs) are validated herein for this purpose.
METHODS: Commutability of 16 candidate CRM formats was assessed across five CSF Aβ42 immunoassays and one mass spectrometry (MS) method in a set of 48 individual clinical CSF samples. Promising candidate CRM formats (neat CSF and CSF spiked with Aβ42) were identified and subjected to validation across eight (Elecsys, EUROIMMUN, IBL, INNO-BIA AlzBio3, INNOTEST, MSD, Simoa, and Saladax) immunoassays and the MS method in 32 individual CSF samples. Commutability was evaluated by Passing-Bablok regression and the candidate CRM termed commutable when found within the prediction interval (PI). The relative distance to the regression line was assessed.
RESULTS: The neat CSF candidate CRM format was commutable for almost all method comparisons, except for the Simoa/MSD, Simoa/MS and MS/IBL where it was found just outside the 95% PI. However, the neat CSF was found within 5% relative distance to the regression line for MS/IBL, between 5% and 10% for Simoa/MS and between 10% and 15% for Simoa/MSD comparisons.
CONCLUSIONS: The neat CSF candidate CRM format was commutable for 33 of 36 method comparisons, only one comparison more than expected given the 95% PI acceptance limit. We conclude that the neat CSF candidate CRM can be used for value assignment of the kit calibrators for the different Aβ42 methods.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26495928     DOI: 10.1515/cclm-2015-0733

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  25 in total

Review 1.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

2.  Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator Material.

Authors:  Kyra J Cowan; Lakshmi Amaravadi; Mark J Cameron; Damien Fink; Darshana Jani; Medha Kamat; Lindsay King; Robert J Neely; Yan Ni; Paul Rhyne; Renee Riffon; Yuda Zhu
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

Review 3.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

4.  Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.

Authors:  Magdalena Korecka; Michal J Figurski; Susan M Landau; Magdalena Brylska; Jacob Alexander; Kaj Blennow; Henrik Zetterberg; William J Jagust; John Q Trojanowski; Leslie M Shaw
Journal:  Clin Chem       Date:  2020-04-01       Impact factor: 8.327

Review 5.  Diagnosis of neurodegenerative dementia: where do we stand, now?

Authors:  Giulia M Sancesario; Sergio Bernardini
Journal:  Ann Transl Med       Date:  2018-09

6.  The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.

Authors:  Ann De Vos; Hanne Struyfs; Dirk Jacobs; Erik Fransen; Tom Klewansky; Ellen De Roeck; Caroline Robberecht; Christine Van Broeckhoven; Charles Duyckaerts; Sebastiaan Engelborghs; Eugeen Vanmechelen
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

7.  Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.

Authors:  Antoine Leuzy; Konstantinos Chiotis; Steen G Hasselbalch; Juha O Rinne; Alexandre de Mendonça; Markus Otto; Alberto Lleó; Miguel Castelo-Branco; Isabel Santana; Jarkko Johansson; Sarah Anderl-Straub; Christine A F von Arnim; Ambros Beer; Rafael Blesa; Juan Fortea; Sanna-Kaisa Herukka; Erik Portelius; Josef Pannee; Henrik Zetterberg; Kaj Blennow; Agneta Nordberg
Journal:  Brain       Date:  2016-07-07       Impact factor: 13.501

Review 8.  Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.

Authors:  Lih-Fen Lue; Andre Guerra; Douglas G Walker
Journal:  Neurol Ther       Date:  2017-07-21

9.  Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.

Authors:  Hugo Marcel Johan Vanderstichele; Shorena Janelidze; Leentje Demeyer; Els Coart; Erik Stoops; Victor Herbst; Kimberley Mauroo; Britta Brix; Oskar Hansson
Journal:  J Alzheimers Dis       Date:  2016-05-31       Impact factor: 4.472

Review 10.  Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.

Authors:  Stephen P Arnerić; Richard Batrla-Utermann; Laurel Beckett; Tobias Bittner; Kaj Blennow; Leslie Carter; Robert Dean; Sebastiaan Engelborghs; Just Genius; Mark Forrest Gordon; Janice Hitchcock; June Kaplow; Johan Luthman; Richard Meibach; David Raunig; Klaus Romero; Mahesh N Samtani; Mary Savage; Leslie Shaw; Diane Stephenson; Robert M Umek; Hugo Vanderstichele; Brian Willis; Susan Yule
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.